Insider Trading By Ex-FDA Official Puts Spotlight On Current Agency Practices
This article was originally published in The Pink Sheet Daily
After Office of Generic Drugs Deputy Director Gordon Johnston left FDA, he joined GPhA and 'tricked' a former colleague into sharing info on generic Lovenox on behalf of a hedge fund he was secretly working for, SEC says.
You may also be interested in...
Academic authors say that more than half of FDA medical reviewers leave to either work or consult to industry; experts chime in with mixed reactions to the findings.
House Energy & Commerce Committee leaders ask what additional steps agency has taken to safeguard trade secrets in wake of insider trading charges against former FDA official.
In past month, three individuals in biopharma space have been charged with insider trading despite efforts by companies and associations to protect confidential information; past sentencing suggests length of jail time former FDA official Gordon Johnston is likely to face.